Delighted to share our new review on HER2 and urothelial carcinoma - from biology to biomarkers and therapeutic perspectives - now out in @NatRevUrol! Huge thanks to all the co-authors for this outstanding collaboration 🙌 @MattGalsky @emanuele_crupi @Pederfizzo @OncoAlert

Adaptive radiotherapy in #BladderCancer: Phase II results from the #RAIDERII trial. @robert_huddart @ICR_London joins @UroCancerMD @VUMCurology to discuss. Daily imaging & tailored plans for improved treatment precision for 98% of patients with low toxicity & promising disease

https://t.co/MtsNvSntD6

Want to work in the cutting edge Uro-oncology unit at the Royal Marsden? An opportunity to work with #alisontree, #chrisparker, #shaistahafeez, #juliamurray among others. We are looking for TWO clinical oncologists to join us. Link to application below

@RTTQA_UK @RMresearch_

News for UK radiotherapy community. Pleased to say that thanks to @macmillancancer we have been able to establish #ctrad. We plan a proposals guidance meeting on 8.7.25 If you have a new trial idea, wish to attend please contact ctrad@macmillan.org to register. @RCRadiologists

Excited to share that our narrative review on the management of testicular cancer is now online at @JCOOP_ASCO Read here: https://t.co/9i5P1HAgCm @DanieleRaggi83 @robert_huddart @ASCO @JCO_ASCO @TestesCancer @TesticularUK @TCSociety @CheckOneTwoPod

Adaptive radiotherapy in #BladderCancer: Phase II results from the #RAIDERII trial. @robert_huddart @ICR_London joins @UroCancerMD @VUMCurology to discuss. Daily imaging & tailored plans for improved treatment precision for 98% of patients with low toxicity & promising disease

Great honor to be at #ESTRO25 to discuss the bladder sparing approach with medical tx alone in #MIBC. Challenging topic pending EV-P combo in EV304 study. Patient's selection remains critical. @robert_huddart @fontev1 @GiulioFrancoli1 @StAr_MCM74 @OncoAlert @WorldBladderCan

🎯 major takeaways from the brilliant presentation on bladder sparing treatment by @robert_huddart #ESTRO2025

One of the best scientific debates I’ve witnessed between Prof Mike Seckl @ImperialNHS and Prof @robert_huddart @royalmarsdenNHS on management of brain mets in GCT patients. Thank you both for a superb session. #NGCGEaling25 @NGermCellG

Adaptive radiotherapy in #BladderCancer: Phase II results from the #RAIDERII trial. @robert_huddart @ICR_London joins @UroCancerMD @VUMCurology to discuss. Daily imaging & tailored plans for improved treatment precision for 98% of patients with low toxicity & promising disease

[3/3] Robert Huddart, Fay Cafferty and Alison Reid received a Clinical Trial Award to assess circulating serum microRNA as a #biomarker for relapse in Phase 2/3 trial to reduce the burden of standard active surveillance in stage I germ cell tumours. #CRUKFunded #tyacancer

#RAIDER trial: Safety of tumor-directed dose escalation. 💡 Adaptive radiotherapy reshapes bladder cancer care! Dr. @robert_huddart @ICR_London and @l_ballas discuss RAIDER trial findings: safe dose escalation, low toxicity, and preserved quality of life using tumor-directed

💫🌟🔬 Unraveling the Genetic Landscape of Testicular Germ Cell Tumors (TGCT)! 🧬🌟💫 ❗️Largest whole-exome meta-analysis in TGCT to date sheds light on genetic predisposition in 1,435 cases vs. 18,284 controls. #ZeidKuzbari @CRowlandsBio #IsaacWade #AliceGarrett @LovedayChey

@robert_huddart @PaulSargos @DrYukselUrun @ZilliThomas @ASCO @OncoAlert @CCR_AACR @MattGalsky @PGrivasMDPhD @yekeduz_emre @drenriquegrande @ProfSyedHussain @ERPlimackMD @alison_tree @tompowles1 @cdanicas @Prof_Nick_James Agree @robert_huddart @PaulSargos Results from contemporary #radiotherapy trials are as good as these with a lot less toxicity. I've said it before & I'll say it again - there's already an excellent alternative to cystectomy. #RAIDER https://t.co/28O2Qo0fxA

🎯Amazing session on testicular cancer! So exciting to see new therapeutic approaches on the horizon. ✨CAR T-cells, ADCs, and bispecifics targeting Claudin 6 – the future is bright! #ASCOGU25 @DrDarrenFeldman @nabiladra @robert_huddart @urofocus @oncodaily

@robert_huddart presenting intriguing data on combining pembrolizumab and radiation for locally advanced/metastatic bladder cancer: 24 Gy in 6 fractions, with 13/26 patients responding per RECIST and 8 achieving CR @ASCO #GU25

📢 Out Now! Tune in to a must-listen episode with Dr Anna Kirby! We delve into breast cancer radiotherapy trials and reflect on her role as @ESTRO_RT president! @AnnaKirby17 @ICR_London @MRCCTU @royalmarsdenNHS @Hoda_Aty @Prof_Nick_James https://t.co/ORPEqymcGw

#RAIDER trial: Safety of tumor-directed dose escalation. 💡 Adaptive radiotherapy reshapes bladder cancer care! Dr. @robert_huddart @ICR_London and @l_ballas discuss RAIDER trial findings: safe dose escalation, low toxicity, and preserved quality of life using tumor-directed